The potential immunosuppressive effect of an anti-CD154 monoclonal antibody (mAb) on the pathogenic autoreactive T-cell response was evaluated using an in vitro culture system with glycoprotein IIb/IIIa (GPIIb/IIIa)-reactive T cells from patients with immune thrombocytopenic purpura ( 
Introduction
Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by increased platelet destruction caused by antiplatelet autoantibodies, which mainly target glycoprotein IIb/ IIIa (GPIIb/IIIa). 1, 2 We have recently found that GPIIb/IIIa-reactive CD4 ϩ T cells from patients with ITP have helper activity that promotes production of anti-GPIIb/IIIa antibodies capable of binding to normal platelets, indicating that these autoreactive T cells are involved in the pathogenic process of ITP. [3] [4] [5] Therefore, the GPIIb/IIIa-reactive T cell is a reasonable target for a therapeutic strategy that selectively suppresses the pathogenic autoimmune response in patients with ITP. One candidate strategy is the disruption of a costimulatory signal by blocking the interaction between CD40 on antigen-presenting cells (APCs) and CD154 (also known as CD40 ligand) on activated CD4 ϩ T cells; this interaction is essential for the T cell-dependent humoral immune response. 6, 7 The efficacy of blocking this interaction therapeutically with anti-CD154 monoclonal antibody (mAb) has been shown in animal models for various autoimmune diseases. [8] [9] [10] Thus, blockade of the CD40/CD154 interaction has been proposed as a strategy for treating autoimmune diseases 11 and is currently being used in preclinical and clinical studies. 12, 13 In animal models, the CD40/CD154 blockade inhibits the expansion and effector functions of pathogenic autoreactive T cells 9, 10 and even induces long-term antigen-specific tolerance, 14 although the details of the immunoregulatory action remain to be elucidated. In this study, to examine the potential of applying CD40/CD154-targeted intervention to the treatment of ITP, we investigated the ability of anti-CD154 mAb to suppress the T-cell response to GPIIb/IIIa in patients with ITP using in vitro culture systems.
Study design Patients
We studied cells from 5 patients with ITP (ITP1, 10, 11, 14, and 19), all of whom had been enrolled in our previous study. 4 All samples were obtained after the patients gave their written informed consent, approved by the Institutional Review Board of Keio University School of Medicine, Tokyo.
Effects of anti-CD154 mAb on GPIIb/IIIa-induced T-cell responses in bulk T-cell cultures
Peripheral blood mononuclear cells (PBMCs) were used to analyze the direct effects of anti-CD154 mAb on T-cell proliferation and anti-GPIIb/IIIa antibody production induced by trypsin-digested human GPIIb/IIIa. 3 IgG anti-GPIIb/IIIa antibodies in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA) using purified human GPIIb/ IIIa as an antigen. 3 Serial dilutions of anti-CD154 mAb (0.25-2 g/mL; Ancell, Bayport, MN), or anti-HLA-DR, anti-HLA-DQ, or isotypematched control mAb (1 g/mL; Leinco Technologies, Ballwin, MO) were added at the initiation of the cultures. 15 
Repeated treatment of GPIIb/IIIa-reactive T-cell lines with anti-CD154 mAb
We used 2 GPIIb/IIIa-reactive CD4 ϩ T-cell lines, SiM4 and WY9, generated from ITP14 and ITP10, respectively. These lines had a Th0 cytokine profile with the capacity to induce production of anti-GPIIb/ IIIa antibodies that bound to intact platelets. 4 SiM4 and WY9 recognized recombinant glutathione S-transferase fusion proteins encompassing amino acids 18-259 of GPIIb␣ (IIb␣18-259) and 22-262 of GPIIIa (IIIa22-262), respectively, in an HLA-DR-restricted manner. 4 Two tetanus toxoid (TT)-reactive CD4 ϩ T-cell lines generated from a healthy donor were used as controls. 16 After being rested for 10 days, T-cell lines (2 ϫ 10 5 ) were stimulated with IIb␣11-259, IIIa22-262, or TT (5 g/mL), interleukin 2 (IL-2; 50 U/mL), and irradiated autologous lymphoblastoid B-cell line (10 6 ) as APCs for 7 days in the presence of anti-CD154 or isotype-control mAb (2 g/mL). This treatment was repeated for up to 5 rounds. The viable T cells were recovered and subsequently examined for their ability to proliferate and promote anti-GPIIb/IIIa antibody production from autologous B cells in response to antigenic stimulation. 4 In some experiments, anti-CD154 mAbtreated GPIIb/IIIa-reactive T-cell line WY9 was washed twice, serially diluted, and added to cultures of untreated WY9 and autologous B cells to evaluate its effect on anti-GPIIb/IIIa antibody production in the presence or absence of anti-IL-10 mAb (10 g/mL; R & D Systems, Minneapolis, MN). To determine cytokine profiles of GPIIb/IIIareactive T-cell lines treated with anti-CD154 or isotype-control mAb, T cells were stimulated with phorbol myristate acetate and ionomycin for 48 hours, and the amounts of interferon ␥ (IFN-␥), IL-2, IL-4, IL-6, and IL-10 in culture supernatants were measured using commercial ELISA kits (Biosource International, Camarillo, CA). 16 
Statistical analysis
All comparisons were tested for statistical significance using the MannWhitney U test.
Results and discussion
The effects of anti-CD154 mAb on T-cell responses induced by trypsin-digested GPIIb/IIIa were examined in PBMC cultures from 5 patients with ITP, and similar results were obtained from all samples. As shown in Figure 1A -B, anti-CD154 mAb had no effect on the proliferative response of T cells with GPIIb/IIIa, but inhibited anti-GPIIb/IIIa antibody production in a dose-dependent manner. A similar inhibitory effect of anti-CD154 mAb on in vitro T cell-dependent antibody production was reported for an anti-TT antibody response in human splenocyte cultures 17 as well as autoantibody responses in patients with autoimmune diseases. 15, 18, 19 It has been proposed that failure to deliver the essential costimulatory signal during the T cell-APC interaction would result in a state of T-cell anergy, a cellular state in which T cells fail to proliferate when optimally restimulated by an antigen. 20 To test whether blockade of the CD40/CD154 interaction induces an anergic state in autoreactive T cells, GPIIb/IIIareactive T-cell lines were repeatedly stimulated by a GPIIb/IIIa fragment, APCs, and anti-CD154 mAb. The number of viable cells recovered apparently decreased after 2 rounds of the anti-CD154 mAb treatment, and too few T cells to analyze were recovered after 4 rounds of treatment. As shown in Figure 1C , antigen-specific proliferation of GPIIb/IIIa-reactive T cells gradually decreased after repeated anti-CD154 mAb treatment, but not after treatment with isotype-matched control mAb. The anti-CD154 mAb-treated T cells lost their helper activity for promoting anti-GPIIb/IIIa antibody production ( Figure 1D ). The treatment of GPIIb/IIIa-reactive T cells with TT or without antigen and the treatment of TT-reactive T-cell lines with IIb␣18-259 failed to induce an anergic state, indicating that anti-CD154 mAb-induced T-cell anergy is antigen dependent and antigen specific. In GPIIb/IIIa-reactive T-cell lines treated twice with anti-CD154 mAb, production of IFN-␥, IL-2, and IL-6 was greatly reduced, but IL-10 production was preserved (Figure 2A ), resulting in a cytokine profile with low IFN-␥ and high IL-10, similar to the profile of CD4 ϩ regulatory T cells. 21 The anergic GPIIb/IIIa-reactive T-cell line WY9 inhibited anti-GPIIb/IIIa antibody production mediated by untreated WY9 ( Figure 2B ). Neutralization of IL-10 by anti-IL-10 mAb abolished the suppressive effect of the anti-CD154 mAb-treated anergic T cells, indicating that the effector function of GPIIb/IIIareactive CD4 ϩ T cells could be suppressed by bystander GPIIb/IIIa-reactive anergic T cells, partly through the relatively augmented IL-10 production.
Several mechanisms for the in vivo suppressive effects of anti-CD154 mAb on the specific T-cell response have been proposed, including suppression of Th1-type immune response, 9,10 up-regulation of cytotoxic T lymphocyte-associated antigen 4 on T cells, 10 and induction of regulatory cells sharing properties of natural killer and dendritic cells. 22 Here, using a human in vitro culture system, we found a novel mechanism, that is, suppression of T-cell effector function through the induction of antigen-specific anergic T cells with potential regulatory function. The in vitro suppressive effect of anti-CD154 mAb on the pathogenic GPIIb/IIIa-reactive T-cell responses strongly suggests potential utility of CD40/CD154-targeted immune interventions in therapy for ITP and other autoimmune diseases. However, anti-CD154 mAb has been reported to induce thromboembolic events in primates and humans. 23 Therefore, when anti-CD154 mAb is used therapeutically, we have to pay special attention to its potential effects on formation and stabilization of thrombi, which are mediated by CD154 expressed on activated platelets. 24,25 
